CRISPR-based in vivo gene editing biotech Intellia voluntarily paused their Phase III ATTR PN and ATTR CM trials this morning after adverse liver effects in 1 patient.
Road towards the first commercially successful gene therapy continues to be rocky.
CRISPR-based in vivo gene editing biotech Intellia voluntarily paused their Phase III ATTR PN and ATTR CM trials this morning after adverse liver effects in 1 patient.
Road towards the first commercially successful gene therapy continues to be rocky.